Novo Nordisk turns up the heat on inlicensed Genmab drug with phase III preparations

Despite the fact that Novo Nordisk has yet to publicize data from a phase II trial of hemophilia drug Mim8, which the company has developed through a license agreement with Genmab, recruitment for a future phase III study has already begun.

Photo: Novo Nordisk / PR

At Novo Nordisk, preparations are being made to begin a phase III trial of candidate Mim8, which the Danish company hopes to make a blockbuster drug – a drug expected to reach sales of over USD 1bn a year.

The preparations are being made despite the fact that Novo Nordisk has yet to present its data from a currently ongoing phase II study of the candidate. The company has previously stated that it expects results to be ready for publishing before the end of 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs